Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Summary

Pasithea Therapeutics (NASDAQ: KTTA), a clinical-stage biotech company, will participate in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The company's CEO, Dr. Tiago Reis Marques, will deliver a presentation on September 10, 2025, at 2:30 PM ET at the Lotte New York Palace Hotel.

Pasithea is currently developing PAS-004, a next-generation macrocyclic MEK inhibitor. Management will be available for one-on-one meetings throughout the conference, which runs from September 8-10, 2025.

MIAMI, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced management will participate in the H.C. Wainwright 27^th Annual Global Investment Conference, taking place September 8-10, 2025 in New York City.

Pasithea CEO, Dr. Tiago Reis Marques, will deliver a live company presentation and management will be available for one-on-one meetings throughout the event.

Details of the presentation are as follows:

Event: H.C. Wainwright 27^th Annual Global Investment Conference
Date: September 10, 2025
Time: 2:30 PM ET
Location: Lotte New York Palace Hotel
Webcast: Register

About Pasithea Therapeutics Corp.

Pasithea is a clinical-stage biotechnology company primarily focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The Company is currently testing PAS-004 in a Phase 1 clinical trial in advanced cancer patients (NCT06299839), and a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NCT06961565).

Forward Looking Statements

This press release contains statements that constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the Company’s ongoing Phase 1 clinical trial of PAS-004 in advanced cancer patients, the Company’s Phase 1/1b clinical trial of PAS-004 in adult NF1 patients, and the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD) and preliminary efficacy of PAS-004, as well as all other statements, other than statements of historical fact, regarding the Company’s current views and assumptions with respect to future events regarding its business, as well as other statements with respect to the Company’s plans, assumptions, expectations, beliefs and objectives, the success of the Company’s current and future business strategies, product development, pre-clinical studies, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth and financing opportunities and other statements that are predictive in nature. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including risks that future clinical trial results may not match results observed to date, may be negative or ambiguous, or may not reach the level of statistical significance required for regulatory approval, as well as other factors set forth in the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other filings made with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.

Pasithea Therapeutics Contact

Patrick Gaynes
Corporate Communications
pgaynes@pasithea.com

FAQ

When is Pasithea Therapeutics (KTTA) presenting at the H.C. Wainwright Conference?

Pasithea Therapeutics will present on September 10, 2025 at 2:30 PM ET at the Lotte New York Palace Hotel in New York City.

Who will be presenting for Pasithea Therapeutics (KTTA) at the H.C. Wainwright Conference?

Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics, will deliver the company presentation.

What is Pasithea Therapeutics' (KTTA) main product in development?

Pasithea is developing PAS-004, a next-generation macrocyclic MEK inhibitor.

Will there be one-on-one meeting opportunities with Pasithea Therapeutics management?

Yes, management will be available for one-on-one meetings throughout the conference, which runs from September 8-10, 2025.